Treatment status in patients with secondary hyperparathyroidism

doi:10.3877/cma.j.issn.2095-3216.2013.02.004

Abstract

Abstract:

Secondary hyperparathyroidism (SHPT) is an important complication of chronic kidney disease (CKD), which contributes to the skeleton changes, increases the risk of soft tissue and vascular calcifications, and becomes an important predictor of cardiovascular events and mortality. The discovery of fibroblast growth factor-23 and calcium-sensing receptors offered basis for revealing pathogenesis of SHPT. Kidney Disease Outcomes Quality Initiative (K/DOQI) and Kidney Disease Improving Global Outcomes (KDIGO) published the guidelines for mineral and bone disorder of chronic kidney disease,which provided the therapeutic goal for SHPT. Not only the development of new phosphate binders,vitamin D analogues and calcium-sensing receptors agonists, but also the improvement of dialysis patterns and surgical methods, can reduce the PTH level of CKD stages 3 - 5 patients. This review focuses on the treatment status of secondary hyperparathyroidism.

Key words: Secondary hyperparathyroidism, Chronic kidney disease, Hyperphosphatemia

Ying LI. Treatment status in patients with secondary hyperparathyroidism[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2013, 02(02): 70-75.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2013.02.004

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2013/V02/I02/70

References 32

1	National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease [J].Am J Kidney Dis, 2003, 42(4 Suppl 3): S1-S201.
2	Tentori F. Mineral and bone disorder and outcomes in hemodialysis patients: results from the DOPPS [J]. Semin Dial.2010, 23(1): 10-14.
3	Kong XL, Zhang LX, Zhang L, et al. Mineral and bone disorder in Chinese dialysis patients: a multicenter study [J]. BMC Nephrology. 2012, 13: 116.
4	Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group.KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease-Mineral and Bone Disorder(CKD-MBD) [J].Kidney Int. 2009, Suppl 113: S1-S130.
5	Walsh M, Manns BJ, Klarenbach S, et al.The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial [J]. Hemodial Int,2010, 14(2): 174-181.
6	Pierratos A, Ouwendyk M, Francoeur R, et al. Nocturnal hemodialysis: three-year experience [J]. J Am Soc Nephrol. 1998,9(5): 859-868.
7	Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study[J]. J Am Soc Nephrol,2005, 16(9):2778-2788.
8	Maduell F, Navarro V, Torregrosa E, et al. Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration[J]. Kidney Int,2003, 64(1): 305-313.
9	Block GA, Raggi P, BellasiA ,et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients[J]. Kidney Int.2007, 71(5): 438-441.
10	方艺, 丁小强, 邹建洲等. 盐酸司维拉姆治疗维持性血液透析患者高磷血症的短期疗效[J]。中华肾脏病杂志. 2012, 28(3):183-188.
11	Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis[J]. Clin J Am Soc Nephrol, 2008, 3(4): 1125 -1130.
12	Delmez J, Block G, Robertson J, et al. A randomized, doubleblind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis[J]. Clin Nephrol,2007, 68(6): 386-391.
13	Hutchison AJ, Laville M, SPD405-313 Lanthanum Study Group. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden[J]. Nephrol Dial Transplant,2008, 23(11): 3677-3684.
14	Spiegel DM, Farmer B, Smits G, Chonchol M. Magnesium carbonate is an effective phos-phate binder for chronic hemodialysis pa-tients: a pilot study[J]. J Ren Nutr,2007, 17(6):416-422.
15	Chen JB, Chiang SS, Chen HC, et al.Efficacy and safety of SBR759, a novel calcium-free, iron ( Ⅲ ) -based phosphate binder, in Asian patients undergoing hemodialysis a 12-week,randomized, open-label, dose-titration study versus sevelamer hydrochloride[J]. Nephrology, 2011, 16( 8) : 743-750.
16	Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease[J].Clin Nephrol,2010 ,74(1):4-11.
17	McIntyre CW, Pai P, Warwick G, et al. Iron-magnesium hydroxycarbonate ( fermagate ) : a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients[J]. Clin J Am Soc Nephrol. 2009, 4( 2 ): 401-409.
18	Eto N, MiyataY, Ohno H, et al. Nicotinamide prevents the development of hyperphophatemia by suppressing intestinal sodium dependent phosphate transporter in rats with adenine induced renal failure[J]. Nephrol Dial Transplant. 2005, 20(7):1378-1384.
19	Sampathkumar K, Sooraj YS, Ajeshkumar RP, et al. Extended Release nicotinic acid is a promising agent for phosphate control in hemodialysis [J]. Kidney Int. 2006, 69(7): 1281.
20	Kurihara S, Tsuruta Y, Akizawa T, et al. Effect of MCI-196(colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, shortterm trial [J]. Nephrol Dial Transplant, 2005, 20( 2): 424 -430.
21	程叙扬, 甘红兵, 吕继成等. 药用活性炭有效降低顽固性高磷血症透析患者血磷水平与钙磷乘积 [J]. 中华肾脏病杂志.2012, 28(1): 21-24.
22	Sprague SM, Llach F, Amdaid M. Paricalcitsl versus calcitriol in the treatment of secondary hyperparathymidism [J]. Kidney Int,2003, 63(4): 1483-1490.
23	Hayashi M, TsuehiyaY, ltaya Y, et al. Comparison ofthe effects of ealcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic hemedialysis：a randomized prospective multicentre trial [J]. Nephrol Dial Transplant, 2004, 19(8): 2067-2073.
24	Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy [J]. N Engl J Med, 2003, 349(5): 446-456.
25	Zhang Q, Li M, You L, et al. Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis [J]. PLoS One, 2012, 7(10): e48070.
26	Ureña P, Fouque D, Brunet P, et al. Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients in realworld clinical practice-The ECHO observational study: French experience [J]. Nephrol Ther, 2012, 8(7): 527-533.
27	Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl [J]. Kidney Int, 2005, 67(2): 760-771.
28	Coyne DW. Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease [J]. Nat Clin Pract Nephrol, 2008, 4(7): 364-365.
29	de Francisco AL, Piñera C, Palomar R. Cinacalcet should be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease [J]. Nat Clin Pract Nephrol, 2008, 4(7): 366-367.
30	The EVOLVE Trial Investigators. Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis [J]. N Engl J Med. 2012 , 367(26): 2482-2494.
31	Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study:a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis [J]. Nephrol Dial Transplant, 2011, 26(4): 1327-1339.
32	Shih ML, Duh QY, Hsieh CB, et a1.Total parathyroidectomy without autotransplantation for secondary hyperparathyroidism[J]. World J Surg, 2009, 33(2): 248-254.

[1]	Xiaoqing Tang, Ping He, You Yang, Xia Luo, Juying Zhang, Xin Yang, Jinhong Yu. Correlation of sound touch elastography combined with pulsed wave Doppler ultrasound imaging parameters with stage of early chronic kidney disease and their clinical significance [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(05): 491-499.
[2]	Shuxun Ling, Yue Tu, Siyi Liu. Visualization analysis on knowledge map of mesenchymal stem cells in the research field of chronic kidney disease [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(02): 73-82.
[3]	Branch of Organ Transplant of Chinese Medical Association, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association. Clinical practice guidelines for kidney injury management of liver transplant recipients in China(2023 edition) [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(03): 276-288.
[4]	Bokai Cheng, Guang Yang. Progress of research on application of hyperinsulinemic-euglycemic clamp technique for assessing insulin resistance in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 334-339.
[5]	Rongrong Feng, Xiaole Su, Lihua Wang. Research progress on biological markers related to complication of cardiovascular disease in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 273-278.
[6]	Junnan Guo, Hui Lin, Yilin Ren, Xi Qiao. Progress of research on the role of amino acid metabolism disturbance in the transition from AKI to CKD [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 283-287.
[7]	Xiaolong Wang, Jie Wu, Shuwei Duan, Chaohui Wang, Na Pan, Yuanyuan Bai, Hangtian Li, Guangyan Cai. Effect of different levels of physical activity on the prognosis of patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(03): 121-128.
[8]	Yinan Zhang, Guozhen Zhu. Research progress on the transition from acute kidney injury to chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 106-112.
[9]	Yansheng Wu, Xianwen Zhang, Lin Wang. Research progress on the relationship between intestinal microecology and immunity in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 101-105.
[10]	Jinyi Zhang, Yuehong Li. Research progress on the efficacy and strategy of SARS-CoV-2 vaccination in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 97-100.
[11]	Wuhao Xiao, Kanghan Liu. Research progress on the treatment of osteoporosis in patients with advanced chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 92-96.
[12]	Peipei Xi, Jiajun Zhou. Progress in research of sarcopenia in patients with chronic kidney disease: pathogenesis, diagnosis, and treatment [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(05): 491-495.
[13]	Meiju Wei, Ling Pan. Role of gut microbiota-bile acid metabolism axis in chronic kidney disease [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(02): 219-222.
[14]	Caijun Yuan, Ping Wen, Lingling Xu. Advancements in application of continuous glucose monitoring in patients with chronic kidney disease and diabetes [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(01): 79-82.
[15]	Ting Luo, Lingzhi Qiu, Dong Yi, Hua Yan. Research progress on the relationship between mitochondrial dysfunction and cardiovascular disease, ischemic stroke and chronic kidney disease [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2024, 18(01): 60-63.

Please choose a citation manager

Content to export